09-05-2024
|
|
|
Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated May 09, 2024, titled "Solara finalizes Rights Issue terms". |
|
|
|
09-05-2024
|
|
|
Solara Active Pharma Sciences Limited has informed the Exchange that Record date for the purpose of Rights is 15-May-2024. |
|
|
|
09-05-2024
|
|
|
Solara Active Pharma Sciences Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2024, has decided to issue equity shares on rights basis in the ratio of 1 : 3, i.e 1 Equity Shares for every 3 Equity Shares held. Issue Price is 375 per share. |
|
|
|
06-05-2024
|
|
|
SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 09-May-2024 to consider Fund raising. |
|
|
|
26-04-2024
|
|
|
Solara Active Pharma Sciences Limited has informed the Exchange about Loss of Share Certificates |
|
|
|
26-04-2024
|
|
|
SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed the Exchange about Loss of share certificates |
|
|
|
25-04-2024
|
|
|
Solara Active Pharma Sciences Limited has informed the Exchange regarding 'Update on transfer of 100% shareholding in Wholly Owned Subsidiary Company'. |
|
|
|
23-04-2024
|
|
|
Significant movement in price has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Solara Active Pharma Sciences Limited has submitted their response. |
|
|
|
22-04-2024
|
|
|
Solara Active Pharma Sciences Limitedï¿‚ï¾ has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaï¿‚ï¾ (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 |
|
|
|
22-04-2024
|
|
|
Significant movement in price has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
|
|
|
|